To include your compound in the COVID-19 Resource Center, submit it here.

Repatha evolocumab regulatory update

FDA approved the Repatha Pushtronex system to deliver a once-monthly 420 mg subcutaneous dose of Amgen’s Repatha evolocumab to treat patients

Read the full 219 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE